Related Experiment Videos
Benzodiazepines and Electroconvulsive Therapy.
Robert M. Greenberg1, Helen M. Pettinati
1Carrier Foundation, Belle Mead, New Jersey, USA.
Convulsive Therapy
|January 1, 1993
Summary
Oral benzodiazepine (BZD) use during electroconvulsive therapy (ECT) is controversial. Limited data suggest BZDs may shorten seizure duration and reduce ECT efficacy, especially with unilateral ECT.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Benzodiazepines (BZD) exhibit anticonvulsant properties in animal models.
- The clinical impact of BZD use during electroconvulsive therapy (ECT) remains controversial due to conflicting literature and study design limitations.
Purpose of the Study:
- To critically evaluate the existing literature on the effects of oral benzodiazepines on electroconvulsive therapy outcomes.
- To identify methodological challenges in comparing studies on benzodiazepine use and ECT.
Main Methods:
- Review of existing literature on benzodiazepine administration and electroconvulsive therapy.
- Analysis of study design flaws, including retrospective designs, focus on seizure duration, and variations in BZD type/dosage, electrode placement, and stimulus energy.
Main Results:
- Contradictory findings in current literature regarding BZD effects on ECT.
- Studies often lack detailed information on seizure threshold and stimulus energy relationships.
- Limited data suggest BZDs may decrease seizure duration and treatment efficacy, particularly with unilateral ECT.
Conclusions:
- Further well-designed studies are required to definitively ascertain the impact of BZDs on ECT.
- Current limited evidence suggests potential negative effects of BZDs on ECT efficacy, necessitating cautious clinical consideration.